BGU spinout Neuroderm, which is developing clinical-stage pumps containing medicine for Parkinson’s, has been bought by Mitsubishi Tanabe Pharma for $1.1bn.
Neuroderm, an Israel-based Parkinson’s disease therapy spinout of Ben Gurion University of the Negev (BGU), has been bought by Mitsubishi Tanabe Pharma, the pharmaceutical arm of conglomerate Mitsubishi Chemical, for approximately $1.1bn.
Founded in 2003, Neuroderm has a clinical-stage pipeline consisting of three belt-worn pumps that administer liquid medicine subcutaneously, or below skin level, to treat early, mid or late-stage Parkinson’s disease.
The pumps are intended to be safer than invasive surgical operations and more effective than orally-administered…
